Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antibody-directed, effector cell-mediated tumor destruction.

P M Sondel1, J A Hank

  • 1Departments of Human Oncology, Pediatrics, and Genetics, University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, USA. pmsondel@facstaff.wisc.edu

Hematology/Oncology Clinics of North America
|October 26, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antibody landscape of C57BL/6 mice cured of B78 melanoma via immunotherapy.

bioRxiv : the preprint server for biology·2023
Same author

Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial.

Cancer immunology, immunotherapy : CII·2023
Same author

Allele-specific alien-driven diversity, immune responsiveness and MHC-restriction.

Immunology today·2014
Same author

An optimized multi-parameter flow cytometry protocol for human T regulatory cell analysis on fresh and viably frozen cells, correlation with epigenetic analysis, and comparison of cord and adult blood.

Journal of immunological methods·2012
Same author

Immunization by particle-mediated transfer of the granulocyte-macrophage colony-stimulating factor gene into autologous tumor cells in melanoma or sarcoma patients: report of a phase I/IB study.

Human gene therapy·2002
Same author

Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding Gp100 and granulocyte-macrophage colony-stimulating factor.

Clinical cancer research : an official journal of the American Association for Cancer Research·2001

Monoclonal antibody (mAb) therapies show promise for antitumor efficacy, especially in minimal residual disease settings. Combining mAbs with cytokines like IL-2 can enhance immune cell activation for greater antitumor effects.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Monoclonal antibodies (mAbs) are a developing strategy for antitumor treatments.
  • Current research explores mAb efficacy in preclinical and clinical settings.

Purpose of the Study:

  • To evaluate the antitumor efficacy of mAb-based strategies.
  • To investigate the role of mAbs in minimal residual disease (MRD).
  • To assess the combination of mAbs with recombinant cytokines for enhanced immunologic effects.

Main Methods:

  • Utilizing preclinical murine models to test mAb antitumor strategies.
  • Investigating the combination of mAbs with recombinant cytokines (IL-2, IL-12, GM-CSF).
  • Analyzing the recruitment of host immune effector cells by mAbs.

Related Experiment Videos

Main Results:

  • mAb treatment demonstrates antitumor efficacy in animal models and some clinical settings.
  • Preclinical models indicate optimal mAb effectiveness in the minimal residual disease setting.
  • Combining mAbs with cytokines augments immunologic effects by activating effector cells.

Conclusions:

  • Monoclonal antibody therapy shows potential as an antitumor strategy, particularly in MRD.
  • Cytokine combinations with mAbs can enhance immune-mediated antitumor responses.
  • Further clinical trials are investigating these immunotherapeutic approaches.